Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

---

Advances in the treatment of glioma-related signaling pathways and mechanisms by metformin

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 29, 2025

Metformin (MET) is a commonly used drug for the treatment of type 2 diabetes in department endocrinology. In recent years, due to few clinically effective options including glioma, some scholars have proposed possibility metformin and studies shown that has certain inhibitory effect on this tumor. This review explores multiple mechanisms through which exerts its antitumor effects, focusing signaling pathways such as AMPK/mTOR, ferroptosis, autophagy, apoptosis chloride ion channels (CLIC1). Metformin’s inhibition glioma proliferation involves complex cellular processes, mitochondrial dysfunction, increased reactive oxygen species (ROS) production, modulation immune responses. Additionally, affects stem cells by inhibiting key pathways, STAT3, mTOR, AKT, altering tumor microenvironment. While preclinical suggest enhances radiosensitivity reduces recurrence, clinical application remains early stages, with further needed optimize dosing regimens understand full therapeutic potential. provides comprehensive analysis metformin’s molecular highlights potential novel strategy, especially treatment-resistant gliomas.

Language: Английский

---

Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma

Clinical & Translational Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Potential of Curcumin and Its Analogs in Glioblastoma Therapy

Antioxidants, Journal Year: 2025, Volume and Issue: 14(3), P. 351 - 351

Published: March 18, 2025

Curcumin, a polyphenol found in turmeric, demonstrates multifaceted anti-cancer activity against glioblastoma. Its therapeutic potential stems from its ability to modulate various molecular pathways implicated glioblastoma development and progression, enhance the effectiveness of radiation therapy, induce cancer cell death through diverse mechanisms, including apoptosis, autophagy, cycle arrest. These combined actions make curcumin promising candidate for treatment, warranting further investigation into clinical application. In this review, we summarize latest research on analogs' therapy.

Language: Английский

---

Astragaloside IV Relieves Mitochondrial Oxidative Stress Damage and Dysfunction in Diabetic Mice Endothelial Progenitor Cells by Regulating the GSK-3β/Nrf2 Axis

Applied Biochemistry and Biotechnology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Language: Английский

---

Metabolic imbalance and brain tumors: The interlinking metabolic pathways and therapeutic actions of antidiabetic drugs

Pharmacological Research, Journal Year: 2025, Volume and Issue: 215, P. 107719 - 107719

Published: April 2, 2025

Brain tumors are complex, heterogeneous malignancies, often associated with significant morbidity and mortality. Emerging evidence suggests the important role of metabolic syndrome, such as that observed in diabetes mellitus, progression brain tumors. Several studies indicated hyperglycemia, insulin resistance, oxidative stress, altered adipokine profiles influence tumor growth, proliferation, treatment resistance. Intriguingly, antidiabetic drugs (e.g., metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones) have shown promise adjunctive or repurposed agents managing Metformin can impair cell enhance sensitivity, modify microenvironment by activating AMP-activated protein kinase (AMPK) inhibiting mammalian target rapamycin (mTOR) signaling pathways. DPP-4 inhibitors GLP-1 agonists both inflammatory aspects tumors, while thiazolidinediones may induce apoptosis cells synergize other therapeutics. Consequently, further clinical trials needed to confirm efficacy, safety, utility interventions treating Here, we review for interconnections between diseases multiple actions anti-diabetes

Language: Английский

---

Image-Guided Mesenchymal Stem Cell Sodium Iodide Symporter (NIS) Radionucleotide Therapy for Glioblastoma

Published: July 9, 2024

Background: Glioblastoma (GBM) is a highly aggressive, invasive, and growth-factor-independent grade IV glioma. Survival following the diagnosis generally poor, with median survival of approximately 15 months, it considered most aggressive lethal central nervous system tumor. Conventional treatments based on surgery, chemotherapy, radiation therapy only delay progression, death inevitable. Malignant glioma cells are resistant to traditional therapies, potentially due subpopulation stem that invasive capable rapid regrowth. Methods: Systematic retrieval information was performed PubMed. Specified keywords were used in PubMed articles published peer-reviewed scientific journals associated brain GBM cancer, sodium iodide symporter (NIS). Additionally, words 'radionuclide therapy', 'radioiodine', 'iodine-131', 'molecular imaging', 'gene 'translational imaging' used. Other such as ‘glioblastoma', 'targeted', 'theranostic', 'symporter', 'virus', 'solid tumor', 'combined 'pituitary', or 'plasmid' also appropriate literature databases search engines. 19 found this Mesenchymal Stem Cell Sodium Iodide Symporter GBM. \ These from years 2000 2024. Appropriate studies isolated, important each them understood entered into database which article. Results: For long they express functional NIS, mesenchymal systemically repress T B cells; however, after that, largely replaced by generated embryonic functionally competent. As result their natural capacity identify malignancies, MSC employed tumor vehicles. Because MSCs may be transplanted several methods, have been proposed ideal vehicles for NIS gene transfer. Conclusion: Non-invasive imaging-based detection presents an alternate means monitor diagnose evaluate recurrence. The iodine specific variety human thyroid disease functions move cell. In recent years, increasing number related reported tumors therapeutic vectors imaging therapy. Gene nuclear medicine provide new direction.

Language: Английский

---

Image-Guided Mesenchymal Stem Cell Sodium Iodide Symporter (NIS) Radionuclide Therapy for Glioblastoma

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2892 - 2892

Published: Aug. 20, 2024

Glioblastoma (GBM) is a highly aggressive, invasive, and growth factor-independent grade IV glioma. Survival following the diagnosis generally poor, with median survival of approximately 15 months, it considered most aggressive lethal central nervous system tumor. Conventional treatments based on surgery, chemotherapy, radiation therapy only delay progression, death inevitable. Malignant glioma cells are resistant to traditional therapies, potentially due subpopulation stem that invasive capable rapid regrowth. This literature review. The systematic retrieval information was performed PubMed, Embase, Google Scholar. Specified keywords were used in PubMed articles retrieved published peer-reviewed scientific journals associated brain GBM cancer sodium iodide symporter (NIS). Additionally, words 'radionuclide OR mesenchyma, radioiodine iodine-131 molecular imaging gene translational targeted theranostic virus solid tumor combined pituitary plasmid AND glioblastoma GB glioma' also appropriate databases A total 68,244 found this search Mesenchymal Stem Cell Sodium Iodide Symporter GBM. These till 2024. To study recent advances, filter added include from 2014 2024, duplicates removed, not related title excluded. came out be 78 articles. From these, nine seven selected after removal keyword mismatched Appropriate studies isolated, important each them understood entered into database which article. As result their natural capacity identify malignancies, MSCs employed as vehicles. Because may transplanted using several methods, they have been proposed ideal vehicles for NIS transfer. delivery vector anticancer drugs many models move precisely malignancies. Also, by directly injecting radiolabeled malignant tumors, therapeutic dosage beta deposited, benefit would localize spread surrounding healthy tissues. non-invasive imaging-based detection presents an alternate means monitor diagnose evaluate recurrence. specific variety human thyroid diseases functions iodine cell. In years, increasing number reported tumors vectors therapy. Gene nuclear medicine provide new direction. all preclinical reviewed, image-guided cell led greater benefits and, therefore, has potential translated techniques treatment trials.

Language: Английский

---

Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 23, 2024

Language: Английский

---

Synthesis and anti-tumor activity of menthylamine derivatives: Focusing on the potent inhibitory effect of compound W8 on glioma growth

Bioorganic & Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 117, P. 118024 - 118024

Published: Nov. 28, 2024

Language: Английский

---